Overview
The purpose of this study is to determine if BHV-1400 is a safe and tolerable treatment in participants with IgA Nephropathy (IgAN).
Eligibility
Key Inclusion Criteria:
- Participants must have biopsy-confirmed IgA Nephropathy
Key Exclusion Criteria:
- Any secondary IgAN
- Any cause of chronic kidney disease not diagnosed as IgAN or due to non-IgAN cause